Immunome, Inc. Share Price & Technical Analysis
IMNM · $19.81 (+2.43%)
Healthcare / Biotechnology
$19.81
+2.43%
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine …
Price chart
Seasonality
Jun has 2 positive and 3 negative years (last 5 years shown)
-7% return in Jun, 13% avg return in past 3 year Jun month.
-1% return in 2026, 118% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 15% | -11% | 3% | 3% | -5% | -7% | – | – | – | – | – | – | -1% |
| 25 | 3% | -11% | -29% | 31% | 0% | 6% | 14% | -7% | 23% | 40% | 14% | 16% | 101% |
| 24 | 54% | 43% | 2% | -43% | 7% | -19% | 29% | -1% | -4% | -21% | 15% | -24% | 38% |
| 23 | 121% | -12% | 9% | -6% | 11% | 52% | -9% | -11% | 29% | 5% | -14% | 41% | 216% |
| 22 | -30% | -28% | -14% | -31% | 8% | -18% | 18% | 50% | -23% | 0% | -4% | -46% | -118% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Weak
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$2.21B
P/E ratio
—
52W high
$27.65
52W low
$7.96
Volume
12,46,240
Beta
2.12
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹34,400
Abbott Laboratories Cede…
₹32,740
Eli Lilly And Company Ce…
₹28,720
Unitedhealth Group Inc C…
₹17,140
Elevance Health Inc
₹6,770
Frequently asked questions
- What is Immunome, Inc. share price today?
- Immunome, Inc. (IMNM) last traded around $19.81 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does IMNM have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for IMNM. Download the app for real-time alerts.
- How can I analyze Immunome, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.